Matsumura Yayoi, Kuroda Junya, Shimura Yuji, Kiyota Miki, Yamamoto-Sugitani Mio, Kobayashi Tsutomu, Matsumoto Yosuke, Horiike Shigeo, Taniwaki Masafumi
Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan.
Intern Med. 2012;51(19):2785-7. doi: 10.2169/internalmedicine.51.8260. Epub 2012 Oct 1.
No standard therapeutic approaches have so far been established for the treatment of relapsed angioimmunoblastic T-cell lymphoma (AITL), a subtype of non-Hodgkin lymphoma. This case report describes an AITL patient who relapsed with hemophagocytic syndrome (HPS) two months after receiving high-dose chemotherapy (HDCT) supported by autologous peripheral blood stem cell transplantation (PBSCT). The patient was successfully treated with cyclosporine A (CsA) and subsequent allogeneic PBSCT with reduced intensity conditioning regimen (RIST). RIST may deserve consideration for treatment of AITL patients with severe complications such as HPS. Additionally, CsA could be a less-toxic therapeutic option for pre-RIST induction therapy against AITL.
对于非霍奇金淋巴瘤的一种亚型——复发血管免疫母细胞性T细胞淋巴瘤(AITL),目前尚未建立标准的治疗方法。本病例报告描述了一名AITL患者,在接受自体外周血干细胞移植(PBSCT)支持的大剂量化疗(HDCT)两个月后,复发并伴有噬血细胞综合征(HPS)。该患者通过环孢素A(CsA)及随后采用减低剂量预处理方案(RIST)的异基因PBSCT成功得到治疗。RIST对于治疗伴有HPS等严重并发症的AITL患者可能值得考虑。此外,CsA对于AITL的RIST前诱导治疗可能是一种毒性较小的治疗选择。